An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+Advanced Breast Cancer (ABC).

Dirix, L., Machiels, J.-P., Canon, J.-L., Amadori, D., Villa, E., Aldrighetti, D., Verkh, L., Bouko, Y., Kem, K., Giorgetti, C., & Cardoso, F. (2009). An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+Advanced Breast Cancer (ABC). Cancer Research, 69(24), 852S-853S. https://hdl.handle.net/2078.5/71171 (Original work published 2009)